TFK-1人膽管癌細胞

細胞名稱

TFK-1人膽管癌細胞

貨物編碼

BFN60808817

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研   2類

培養體系

90%DMEM+10%FBS+1%三抗

培養溫度

37℃

二氧化碳濃度

5%

簡介

TFK-1人膽管癌細胞取自63歲男性供體。該細胞源于DSMZ

注釋

Doubling time: ~37 hours, at 40th passage (PubMed=8693487); ~40 hours (DSMZ).

Omics: Deep exome analysis.

Misspelling: TFKK-1; PubMed=22490663 supplementary figure 2.

基因突變

/

HLA信息

/

STR信息

Amelogenin        X,Y

CSF1PO        10

D5S818        9,12

D7S820        10 (DSMZ)

10,11 (RCB; TKG)

D13S317        14

D16S539        9

TH01        6

TPOX        8

vWA        14,17

參考文獻

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122

Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M., Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S., Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M., Ishida M., Motoi F., Egawa S., Unno M., Horii A.

DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.

Biochem. Biophys. Res. Commun. 421:98-104(2012)

CLPUB00275

Zach S., Birgin E., Ruckert F.

Primary cholangiocellular carcinoma cell lines.

J. Stem Cell Res. Transplant. 2:1013-1013(2015)

PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442

Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H., Bardeesy N.

Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.

Cancer Discov. 6:727-739(2016)

PubMed=31077409; DOI=10.1002/hep.30704

Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S.

Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.

Hepatology 70:1614-1630(2019)